OncoMatch/Clinical Trials/NCT04417166
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Is NCT04417166 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab for lymphoma, extranodal nk-t-cell.
Treatment: Pembrolizumab — Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy and concurrent pembrolizumab administered intravenously every 3 weeks. After 6 cycles of pembrolizumab patients with complete remission, partial response and stable disease will continue with pembrolizumab maintenance up to 2 years. Patients will be followed up to 4 years from treatment start.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage I, II
Excluded: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 agent
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate hematological and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify